Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 15-02-2016 | Practice Area: | Corporate and M&A |
| Deal Title: | BioGaia AB/Infant Bacterial Therapeutics AB Group Restructuring | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Vinge advised BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) in connection with the proposed distribution of BioGaia's shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT applied for listing of the company's series B shares on Nasdaq First North. IBT was developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
|
||
| Financial Center: | Stockholm | Value: | 0.00-0.00 |
| Advised Party: | Group | Law Firm | Vinge |
| Group | Sweden | Group | Sweden |
| Classification: |
Group Restructurings |
Lawyer | Erik Sjoman |
